Pulse Biosciences (NASDAQ:PLSE) Upgraded to Strong-Buy at BTIG Research

Pulse Biosciences (NASDAQ:PLSE) was upgraded by investment analysts at BTIG Research to a “strong-buy” rating in a research note issued on Wednesday, Zacks reports.

Several other brokerages have also issued reports on PLSE. Wall Street Zen upgraded shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, September 6th. Canaccord Genuity Group increased their price target on shares of Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a report on Friday, July 17th. Finally, Freedom Capital raised shares of Pulse Biosciences to a “strong-buy” rating in a report on Wednesday, September 9th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $50.20.

Pulse Biosciences Stock Down 1.3%

NASDAQ:PLSE opened at $51.98 on Wednesday. The stock has a market cap of $3.68 billion, a P/E ratio of -44.05 and a beta of 1.63. The business’s 50-day moving average price is $44.45 and its two-hundred day moving average price is $30.99. Pulse Biosciences has a twelve month low of $12.56 and a twelve month high of $58.90.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The business had revenue of $0.43 million for the quarter, compared to analysts’ expectations of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. On average, equities research analysts expect that Pulse Biosciences will post -1.29 EPS for the current fiscal year.

Insider Activity at Pulse Biosciences

In related news, COO Liane Teplitsky bought 1,036 shares of the stock in a transaction dated Wednesday, August 26th. The stock was bought at an average price of $48.23 per share, with a total value of $49,966.28. Following the purchase, the chief operating officer owned 1,036 shares in the company, valued at approximately $49,966.28. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders bought a total of 4,095 shares of company stock valued at $199,931 in the last quarter. 74.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Pulse Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Osterweis Capital Management Inc. bought a new stake in Pulse Biosciences in the second quarter valued at approximately $28,000. Jupiter Topco LLC bought a new position in shares of Pulse Biosciences in the second quarter worth approximately $241,000. GSA Capital Partners LLP purchased a new position in shares of Pulse Biosciences in the second quarter worth $290,000. Legal & General Group Plc purchased a new position in shares of Pulse Biosciences in the second quarter worth $395,000. Finally, Cetera Investment Advisers bought a new stake in Pulse Biosciences during the 1st quarter valued at $387,000. 76.95% of the stock is currently owned by institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc is a medical technology company developing proprietary bioelectric therapies based on its Nano-Pulse Stimulation technology. The platform delivers ultrashort electrical pulses designed to affect targeted cells while limiting thermal damage to surrounding noncellular tissue.

The company’s primary product is the CellFX System, which is designed to deliver Nano-Pulse Stimulation treatments for certain dermatological conditions. Pulse Biosciences is also developing additional applications for its technology in areas including cardiac procedures and other medical specialties.

Pulse Biosciences was founded in 2014 and is headquartered in Hayward, California.